Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · July 01, 2024

Effect of Denosumab vs Bisphosphonates on Incidence of Type 2 Diabetes, Risk of Foot Ulceration, and All-Cause Mortality in Adults With Osteoporosis

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis
Diabetes Obes Metab 2024 Jun 20;[EPub Ahead of Print], AE Henney, DR Riley, B O'Connor, TJ Hydes, M Anson, SS Zhao, U Alam, DJ Cuthbertson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading